Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 ,inter alia, to consider and approve As per attachment
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on 13th May 2025. The Board will consider and approve the audited financial results (both standalone and consolidated) for the quarter and full year ended 31st March 2025. The Board will also consider recommending a dividend, if any, on the company's equity shares. The company has filed this under Regulations 29 and 33 of the SEBI Listing Obligations and Disclosure Requirements. No financial figures have been disclosed in this filing as it is only a pre-meeting notice.
This is a routine pre-results announcement and does not itself move the stock. Investors should watch 13th May 2025 for the actual FY25 numbers and any dividend declaration, which could influence short-term price action.